Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors - Kim, Seokuee; Kim, Sujong; Park, Young Suk; Park, Joon Oh; Lim, Ho Yeong; Ahn, Jin Seok; Lee, Jeeyun; Sun, Jong Mu; Kang, Won Ki; Han, RaeO; Kim, Jungryul; Ahn, Myung-Ju (Expert opinion on investigational drugs, 2020)
Keywords: Adult; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Arsenites - administration & dosage; Arsenites - adverse effects; Arsenites - pharmacokinetics; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms - drug therapy; Neoplasms - pathology; Sodium Compounds - administration & dosage; Sodium Compounds - adverse effects; Sodium Compounds - pharmacokinetics; Treatment Outcome; arsenical; Anticancer; KML001; monotherapy; telomere